16th Jun 2022 16:49
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Signs exclusive formulation study collaboration with an unnamed pharmaceutical company, under which Arecor will use its formulation technology platform Arestat to develop liquid formulations of its proprietary products.
The unnamed company will fund the initial development work and will hold the option to acquire the rights to the new formulations and associated intellectual property.
"This collaboration expands our partner portfolio of high-profile pharmaceutical companies. The growing recognition of how the Arestat platform can enhance a broad range of therapeutic products is testament to our expertise and innovation in formulation science," says Chief Executive Officer Sarah Howell.
Current stock price: 352.65 pence
12-month change: up 47%
By Dayo Laniyan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Arecor Therape